Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lobe Sciences Ltd. C.LOBE

Alternate Symbol(s):  LOBEF

Healthcare Drug Manufacturers - Major
Lobe Sciences is a leading “BioPsychedelic” company entering clinical stage development focused on transforming psychedelic medicine to benefit patients of all ages. We are engaged in research and development using psychedelic and non-psychedelic compounds targeting the 5HT2 receptor family. Our team is made up of biotech executives who collectively have managed the development and regulatory approval of revolutionary drugs around the globe.


CSE:LOBE - Post by User

Lobe Sciences Ltd.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by PressReleaseon Jul 07, 2022 10:24am
25 Views
Post# 34808143

New Press Release - Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023

New Press Release - Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biotechnology company committed to discovering and developing psychedelic derived medicines today announced it has developed its initial Phase 1 study...read article.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities